Kamil Ali-Jackson - 03 Jan 2022 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
Chief Legal Officer
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol
ACRS
Transactions as of
03 Jan 2022
Net transactions value
$0
Form type
4
Filing time
05 Jan 2022, 15:33:56 UTC
Previous filing
17 Dec 2021
Next filing
23 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Options Exercise +3,875 +3.4% 118,571 03 Jan 2022 Direct F1
transaction ACRS Common Stock Options Exercise +27,905 +24% 146,476 03 Jan 2022 Direct F1
transaction ACRS Common Stock Options Exercise +6,638 +4.5% 153,114 03 Jan 2022 Direct F1
transaction ACRS Common Stock Options Exercise +7,100 +4.6% 160,214 03 Jan 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Restricted Stock Units Options Exercise $0 -3,875 -100% $0.000000* 0 03 Jan 2022 Common Stock 3,875 Direct F1, F2, F3
transaction ACRS Restricted Stock Units Options Exercise $0 -27,905 -100% $0.000000* 0 03 Jan 2022 Common Stock 34,350 Direct F1, F2, F4
transaction ACRS Restricted Stock Unit Options Exercise $0 -6,638 -100% $0.000000* 0 03 Jan 2022 Common Stock 19,914 Direct F1, F2, F5
transaction ACRS Restricted Stock Units Options Exercise $0 -7,100 -100% $0.000000* 0 03 Jan 2022 Common Stock 28,400 Direct F1, F2, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Kamil Ali-Jackson is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
F2 Represents the number of restricted stock units that were accelerated by mutual agreement between the Reporting Person and the Issuer. The balance of unvested restricted stock units, if any, were forfeited.
F3 The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
F4 The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
F5 The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
F6 The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.